SIGA Technologies, Inc. Stock price

Equities

SIGA

US8269171067

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
8.5 USD +2.16% Intraday chart for SIGA Technologies, Inc. -3.08% +51.79%
Sales 2024 * 191M Sales 2025 * 169M Capitalization 604M
Net income 2024 * 84M Net income 2025 * 78M EV / Sales 2024 * 2.3 x
Net cash position 2024 * 167M Net cash position 2025 * 192M EV / Sales 2025 * 2.43 x
P/E ratio 2024 *
6.97 x
P/E ratio 2025 *
7.14 x
Employees 45
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.16%
1 week-3.08%
Current month+63.15%
1 month+58.29%
3 months+53.71%
6 months+65.69%
Current year+51.79%
More quotes
1 week
7.86
Extreme 7.855
8.93
1 month
4.75
Extreme 4.75
8.98
Current year
4.26
Extreme 4.26
8.98
1 year
4.22
Extreme 4.215
8.98
3 years
4.22
Extreme 4.215
26.99
5 years
3.96
Extreme 3.96
26.99
10 years
0.20
Extreme 0.2
26.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 Jan. 26
Director of Finance/CFO 53 11-02-09
Chief Operating Officer - 97-12-31
Members of the board TitleAgeSince
Director/Board Member 71 09-03-10
Director/Board Member 70 20-06-15
Director/Board Member 53 22-11-09
More insiders
Date Price Change Volume
24-03-27 8.5 +2.16% 802,329
24-03-26 8.32 -0.36% 926,266
24-03-25 8.35 -4.68% 1,052,219
24-03-22 8.76 -1.79% 1,251,010
24-03-21 8.92 +1.71% 1,341,291

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company's lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The Company does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. It uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company's CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock SIGA Technologies, Inc. - Nasdaq